Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Undisclosed major pharmaco to buy Gamida Cell for significant amount; Novartis is the bidder; terminated

Executive Summary

Privately held Gamida Cell Ltd. (stem cell therapeutics and technologies) received a nonbinding proposal to be acquired by an unnamed global pharmaceutical company for what Gamida says is a “significant amount” up front, plus earn-outs tied to development, regulatory, and sales goals. One of the rumored suitors is Novartis AG, and sources say the deal value is upwards of $600mm.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Includes Earnout

Related Companies